Merestinib

Merestinib
INN: Merestinib
Clinical data
Routes of; administration	PO
ATC code	none;
Identifiers
	IUPAC name N-(3-Fluoro-4-{[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;
CAS Number	1206799-15-6;
ChemSpider	29361338;
CompTox Dashboard (EPA)	DTXSID20659635 ;
ECHA InfoCard	100.233.673
Chemical and physical data
Formula	C30H22F2N6O3
Molar mass	552.542 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C;
	InChI InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39); Key:QHADVLVFMKEIIP-UHFFFAOYSA-N;

Merestinib (LY2801653) is an experimental cancer drug in development by Eli Lilly. It is a small molecule inhibitor of MET and several other receptor tyrosine kinases such as MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2.

Meristinib is part of a phase II clinical trial for advanced billiary tract cancer. The study is expected to be complete in April 2018.^[1] Phase II clinical trials for non-small cell lung cancer and solid tumors began in November 2016.^[2]

References

^ "A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer - Full Text View - ClinicalTrials.gov".
^ "Merestinib - Eli Lilly - AdisInsight". adisinsight.springer.com.

[1] "A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer - Full Text View - ClinicalTrials.gov".

[2] "Merestinib - Eli Lilly - AdisInsight". adisinsight.springer.com.

[1]

[2]